Research By Michael Jordan, MD
Post Date: May 7, 2020 | Publish Date: May 6, 2020
“For the first time we have a truly targeted way to treat HLH and a drug with very low toxicity.”
Clinical trial results published in the New England Journal of Medicine show that using emapalumab to treat patients with hemophagocytic lymphohistiocytosis (HLH) saved lives with less toxicity and fewer side effects.
The results represent a significant achievement in a 20-year journey to battle HLH. This study suggests that emapalumab—the first drug ever approved for HLH by the U.S. Food and Drug Administration—when administered with dexamethasone should become the standard of care for ‘second line’ treatment of HLH, Jordan says.
|Original Title:||Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis|
|Published in:||New England Journal of Medicine|
|Publish date:||May 6, 2020|
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.